QED Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.qedtx.com
Clinical Trials
26
Trial Phases
3 Phases
Drug Approvals
9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
An Interventional Study of Infigratinib in Children With Hypochondroplasia
- Conditions
- Hypochondroplasia
- Interventions
- Drug: infigratinib 0.128 mg/kg/day
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06873035
- Locations
- 🇨🇦
Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec, Canada
🇺🇸UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Childrens Hospital Colorado, Aurora, Colorado, United States
Prospective Clinical Assessment Study in Children With Hypochondroplasia
- Conditions
- Hypochondroplasia
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06410976
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Childrens Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's National Hospital, Washington DC, District of Columbia, United States
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo Comparator 0.25 mg/kg/day
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06164951
- Locations
- 🇬🇧
QED Investigative Site, Sheffield, United Kingdom
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- QED Therapeutics, Inc., a Bridgebio company
- Target Recruit Count
- 300
- Registration Number
- NCT05145010
- Locations
- 🇺🇸
University Hospital and UW Health Clinics, Madison, Wisconsin, United States
🇺🇸USCF Benioff Children's Hospital, Oakland, Oakland, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Study of Infigratinib in Children with Achondroplasia
- Conditions
- Achondroplasia
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- QED Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04265651
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- Prev
- 1
- 2
- Next